Ca2+/calmodulin-dependent protein kinase inhibition suppresses post-ischemic arrhythmogenesis and mediates sinus bradycardic recovery in reperfusion
Related Experiment Video
Updated: Feb 17, 2026

Preparation of Human Myocardial Tissue for Long-Term Cultivation
Published on: June 2, 2022
James R Bell1, Claire L Curl, Wendy T K Ip
1Department of Physiology, University of Melbourne, Victoria, Australia.
Background:
Ca(2+)/calmodulin-dependent protein kinase (CaMKII) activation is known to be associated with conditions where the incidence of arrhythmias is increased, and where cardiomyocyte Ca(2+)-overload occurs. The goal of this study was to determine whether CaMKII inhibition in the intact heart may be linked to the suppression of ventricular arrhythmias occurring during reperfusion after an ischemic insult.
Methods:
Non-paced male rat hearts (n = 8-11) were treated with a CaMKII inhibitor (KN93, 2.5 μmol/L) 10 min prior to global ischemia (20 min) and for the initial 10 min of reperfusion. Cardiac mechanical and arrhythmic responses were evaluated under constant pressure perfusion conditions and myocyte damage assessed by measurement of coronary effluent lactate dehydrogenase (LDH).
Results:
Under basal conditions, KN93 increased coronary flow (41 ± 8% increase, p<0.05) and was negatively inotropic (29 ± 7% decrease, p<0.05), but did not affect heart rate. Ischemic contracture was significantly diminished in KN93-treated hearts (onset, min: 11.48 ± 0.50 vs 16.27 ± 1.23, p<0.05). CaMKII inhibition in early reperfusion almost completely abolished the incidence of ventricular tachycardia/fibrillation in reperfusion (11/11 control vs 1/8 KN93). In the absence of ventricular arrhythmias, heart rate was substantially reduced (% basal; 100 ± 3% vs 46 ± 8%, p<0.05) throughout reperfusion. Left ventricular developed pressure was initially low in KN93 hearts post-ischemia, but recovered to control levels by the end of 60 min reperfusion (68 ± 5% vs 56 ± 5%, p = ns). LDH was significantly reduced in KN93-treated hearts.
Conclusion:
Although CaMKII inhibition diminishes contractile performance of the intact heart in the initial post-ischemic period, it provides crucial benefits through protection against potentially lethal reperfusion-induced arrhythmias and cardiomyocyte sarcolemmal rupture.
Insights
Ca(2+)/calmodulin-dependent protein kinase (CaMKII) inhibition significantly reduced reperfusion-induced ventricular arrhythmias and cardiomyocyte damage in rat hearts. While initially decreasing contractile function, CaMKII inhibition proved crucial for protecting the heart post-ischemia.
Area of Science:
- Cardiology
- Molecular Biology
- Physiology
Background:
- Ca(2+)/calmodulin-dependent protein kinase (CaMKII) activation is linked to increased arrhythmia incidence and cardiomyocyte Ca(2+)-overload.
- Understanding CaMKII's role is crucial for developing therapies against heart rhythm disorders.
Purpose of the Study:
- To investigate if CaMKII inhibition suppresses ventricular arrhythmias during reperfusion after ischemia.
- To evaluate the effects of CaMKII inhibition on cardiac function and myocyte damage.
Main Methods:
- Male rat hearts were treated with a CaMKII inhibitor (KN93) before global ischemia and during early reperfusion.
- Cardiac mechanical and arrhythmic responses were assessed, along with myocyte damage via lactate dehydrogenase (LDH) levels.
Main Results:
- KN93 increased coronary flow and was negatively inotropic but did not affect heart rate under basal conditions.
- CaMKII inhibition significantly reduced ischemic contracture and almost abolished ventricular tachycardia/fibrillation during reperfusion.
- LDH levels were significantly reduced, indicating protection against cardiomyocyte damage.
Conclusions:
- CaMKII inhibition diminishes initial post-ischemic contractile performance but offers critical protection against lethal reperfusion arrhythmias.
- This inhibition also protects against cardiomyocyte sarcolemmal rupture, highlighting its therapeutic potential.
Related Concept Videos
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Mechanism of Cardiac Arrhythmias
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
G-Protein Gated Ion Channels
Sensory...

